SURF Research and Charts

SURF - Surface Oncology Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2024-02-05 (Delayed quote data )

Last	Change ⇓ 0.00 (%)	Volume 0
	Open	High	Low

8EMA (Daily) 0.00	40EMA (Daily)	50EMA (Daily)	STO (Daily)	MACD Hist (Daily)
8EMA (Weekly) 0.987	40EMA (Weekly) 1.02	50EMA (Weekly) 1.16	STO (Weekly) 80.316	MACD Hist (Weekly) 0.085


Company Profile
Surface Oncology Inc is a clinical-stage immuno-oncology company. It is developing new therapies that modify the spaces in and around tumors the tumor microenvironment to create conditions that support and sustain anti-tumor immune responses. The company's pipeline products are SRF231, SRF373, SRF617, and SRF388. Geographically, the activities are carried out through the region of the United States.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.